Consumer Health Products
(Source: Persistence Market Research, July 2018)
The global dermatophytic onychomycosis therapeutics market is projected to expand at a compound annual growth rate of 7.6% during the forecast period 2018–2026 and reach a value of US$6.7 billion by the end of 2026.
Market growth is primarily driven by factors such as an increase in the prevalence of fungal toe nail infections in the United States and Canada and rising per capita health care expenditures across the globe.
By treatment, the market is segmented into topical and oral therapy. The topical segment is expected to be dominant throughout the forecast period and projected to account for about 70% share of the total global dermatophytic onychomycosis market revenue by 2021.
with potential pharmaceutical applications
Mondias has two products (fungal relief for athlete’s foot and nail fungus) that have been approved by Health Canada.